Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril

Angiotensin‐converting enzyme (ACE) inhibitors are recommended for patients with chronic kidney disease (CKD) because they slow disease progression. But physicians' concerns about the risk of hyperkalemia (elevated serum potassium level), a potentially fatal adverse effect, may limit optimal management with ACE‐inhibitors. We synthesized known predictors of hyperkalemia into a prognostic risk score to predict the risk of hyperkalemia.

[1]  P. Parfrey.  Inhibitors of the ReninAngiotensin System: Proven Benefits, Unproven Safety , 2008, Annals of Internal Medicine.

[2]  R. Kunz,et al.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the ReninAngiotensin System on Proteinuria in Renal Disease , 2008, Annals of Internal Medicine.

[3]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[4]  M. Zhan,et al.  The frequency of hyperkalemia and its significance in chronic kidney disease. , 2009, Archives of internal medicine.

[5]  Yvonne Vergouwe,et al.  Prognosis and prognostic research: Developing a prognostic model , 2009, BMJ : British Medical Journal.

[6]  P. Royston,et al.  Prognosis and prognostic research: application and impact of prognostic models in clinical practice , 2009, BMJ : British Medical Journal.

[7]  L. Hebert.  Optimizing ACE-inhibitor therapy for chronic kidney disease. , 2006, The New England journal of medicine.

[8]  D. Bates,et al.  Development and validation of a Clinical prediction rule for angiotensin-converting enzyme inhibitor-induced cough , 2004, Journal of General Internal Medicine.

[9]  D. Halpin,et al.  Early identification and management of chronic kidney disease: summary of NICE guidance , 2008, BMJ : British Medical Journal.

[10]  Akram Khan,et al.  Effect of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Serum Potassium Levels and Renal Function in Ambulatory Outpatients: Risk Factors Analysis , 2008, The American journal of the medical sciences.

[11]  Yvonne Vergouwe,et al.  Prognosis and prognostic research: validating a prognostic model , 2009, BMJ : British Medical Journal.

[12]  Yvonne Vergouwe,et al.  Prognosis and prognostic research: what, why, and how? , 2009, BMJ : British Medical Journal.

[13]  R. D'Agostino,et al.  Presentation of multivariate data for clinical use: The Framingham Study risk score functions , 2004, Statistics in medicine.

[14]  G. Eknoyan,et al.  National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification , 2003, Annals of Internal Medicine.

[15]  Yingye Zheng,et al.  Integrating the predictiveness of a marker with its performance as a classifier. , 2007, American journal of epidemiology.

[16]  B. Palmer.  Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. , 2004, The New England journal of medicine.

[17]  L. Appel,et al.  Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. , 2009, Archives of internal medicine.

[18]  Ian Harvey,et al.  A pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers. , 2009, Journal of clinical epidemiology.

[19]  D. Kent,et al.  Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.